AL001

Alector, Inc. is developing AL001 as a new experimental drug for Frontotemporal Dementia (FTD) caused by mutations in the progranulin gene. These mutations reduce the levels of the progranulin protein in the body and may lead to changes in personality, behavior, language and memory.

The goal of treatment with AL001 is to safely increase levels of progranulin in the body which may delay the onset of symptoms or slow the progression of the disease.

The purpose of this clinical research study is to determine if the experimental drug AL001 is effective and safe in treating individuals who have a progranulin gene mutation that causes FTD, when compared to placebo (a solution that contains no active AL001 drug).

ELIGIBILITY

Each individual will be evaluated to determine their eligibility. You may be eligible if:

- You have a progranulin gene mutation and have no FTD symptoms

or

- You are diagnosed with FTD and are have a progranulin gene mutation.

MORE INFORMATION

- AL001 or placebo will be administered every 4 weeks by an intravenous (IV) infusion.
- Assessments will include regular medical examinations, blood tests, brain imaging, and completion of questionnaires.
- For people who have no FTD symptoms:
  - You will be in this study for about 2 years.
  - You will need to visit the study site at least 1 time per month over 2 years.
- For people who are diagnosed with FTD:
  - You will be in this study a little over 1 year.
  - You will need to visit the study site at least 1 time per month over 1 year.

For a list of all Alector Clinical Trials, visit http://bit.ly/Alector_Trials